Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer

Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer

Bibliographic Details
Main Authors:	Rodney P. Rocconi, Laura Stanbery, Min Tang, Luciana Madeira da Silva, Adam Walter, Bradley J. Monk, Thomas J. Herzog, Robert L. Coleman, Luisa Manning, Gladice Wallraven, Staci Horvath, Ernest Bognar, Neil Senzer, Scott Brun, John Nemunaitis
Format:	Article
Language:	English
Published:	Nature Portfolio 2023-05-01
Series:	Communications Medicine
Online Access:	https://doi.org/10.1038/s43856-023-00290-0

Similar Items

ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
by: Rodney P. Rocconi, et al.
Published: (2022-08-01)

Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer
by: Minal Barve, et al.
Published: (2022-08-01)

Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer
by: Rodney P. Rocconi, et al.
Published: (2021-08-01)

Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance
by: Johnathan Oh, et al.
Published: (2020-11-01)

Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6
by: Vedin Barve, et al.
Published: (2021-10-01)

Clonal Neoantigen: Emerging “Mechanism-based” Biomarker of Immunotherapy Response
by: John Nemunaitis, et al.
Published: (2023-11-01)

Vascular CD39/ENTPD1 Directly Promotes Tumor Cell Growth by Scavenging Extracellular Adenosine Triphosphate
by: Lili Feng, et al.
Published: (2011-03-01)

Rationale for the Use of Homologous Recombination Proficient Molecular Profile as a Biomarker for Therapeutic Targeting in Ovarian Cancer
by: John Nemunaitis, et al.
Published: (2023-09-01)

Association of the ENPP1/ENTPD1 Polymorphisms in Hemodialysis Patients
by: Zhang X, et al.
Published: (2021-10-01)

Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma
by: David Kung-Chun Chiu, et al.
Published: (2017-09-01)

Identifying small molecule probes of ENTPD5 through high throughput screening.
by: Matthew A Durst, et al.
Published: (2019-01-01)

Limited TCR repertoire and ENTPD1 dysregulation mark late-stage COVID-19
by: Na Wang, et al.
Published: (2021-10-01)

Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian carcinoma: A systematic review and meta-analysis of randomized controlled trials
by: Yixin Zhang, et al.
Published: (2022-10-01)

Fibrocyte Phenotype of ENTPD1+CD55+ Cells and Its Association with Pain in Osteoarthritic Synovium
by: Maho Tsuchiya, et al.
Published: (2024-04-01)

Procoagulant inhibitory properties of paclitaxel poliglumex
by: John Nemunaitis, et al.
Published: (2010-12-01)

by: Yuqiao Shen, et al.
Published: (2008-04-01)

The UDPase ENTPD5 regulates ER stress-associated renal injury by mediating protein N-glycosylation
by: Lifen Xu, et al.
Published: (2023-02-01)

A novel circular RNA circENTPD7 contributes to glioblastoma progression by targeting ROS1
by: Fei Zhu, et al.
Published: (2020-04-01)

Endothelial Effects of Simultaneous Expression of Human HO-1, E5NT, and ENTPD1 in a Mouse
by: Paulina Mierzejewska, et al.
Published: (2023-10-01)

p53 gain-of-function mutations promote metastasis via ENTPD5 upregulation and enhanced N-glycoprotein folding
by: Oleg Timofeev, et al.
Published: (2017-03-01)

PTEN phosphatase inhibits metastasis by negatively regulating the Entpd5/IGF1R pathway through ATF6
by: Yanlin Yu, et al.
Published: (2023-02-01)

Use of Proteomics Analysis for Molecular Precision Approaches in Cancer Therapy
by: Yuqiao Shen, et al.
Published: (2008-01-01)

Circular RNA ATXN7 promotes the development of gastric cancer through sponging miR-4319 and regulating ENTPD4
by: Zhen Zhang, et al.
Published: (2020-01-01)

Ovarian Cancer Immunotherapy and Personalized Medicine
by: Susan Morand, et al.
Published: (2021-06-01)

Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis
by: Evangelos Pavlakis, et al.
Published: (2023-08-01)

Newly generated items to complement the 39-item Parkinson’s Disease Questionnaire
by: Morley, D, et al.
Published: (2019)

Systemic benefit of radiation therapy via abscopal effect
by: Daniel J. Craig, et al.
Published: (2022-10-01)

Knockdown of ENTPD5 inhibits tumor metastasis and growth via regulating the GRP78/p-eIF-2α/CHOP pathway in serous ovarian cancer
by: Xueping Chen, et al.
Published: (2022-06-01)

SNP-mediated lncRNA-ENTPD3-AS1 upregulation suppresses renal cell carcinoma via miR-155/HIF-1α signaling
by: Jiangyi Wang, et al.
Published: (2021-07-01)

KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex.
by: Donald D Rao, et al.
Published: (2018-01-01)

Pretesting newly generated items to complement the 39- item Parkinson’s disease questionnaire (PDQ)
by: Morley, D, et al.
Published: (2019)

A Scalable Engineered Extracellular Matrix Platform to Expand Tumor Cells
by: Seongjun Moon, et al.
Published: (2023-08-01)

Book Review: ''Epigenetics''
by: Steven G. Gray
Published: (2014-04-01)

Find the word! --- But where? : Maturana's 'Coordination' and Sartre's 'Reflection' around Naming
by: Seiichi eImoto
Published: (2015-11-01)

Adenomatous polyposis coli in cancer and therapeutic implications
by: Olivia Noe, et al.
Published: (2021-06-01)

Deletion of ENTPD3 does not impair nucleotide hydrolysis in primary somatosensory neurons or spinal cord [v1; ref status: indexed, http://f1000r.es/3rm]
by: Eric McCoy, et al.
Published: (2014-07-01)

Adaptation and validation of the Hungarian version of Thyroid-Related Patient-Reported Outcome-39 (ThyPro-39) questionnaire: testing factor structure, known-group validity with the comparison of quality of life in Hashimoto’s thyroiditis and Graves’ disease
by: Adrien Rigó, et al.
Published: (2023-06-01)

Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer
by: Morgan Bailey, et al.
Published: (2024-03-01)

Gut bacterial profile in patients newly diagnosed with treatment-na&iuml;ve Crohn&#39;s disease
by: Ricanek P, et al.
Published: (2012-09-01)

Oil transport inside the oil control ring grove and its interaction with surrounding areas in internal combustion engines
by: Senzer, Eric B
Published: (2012)